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Abstract: The effect of marine-derived omega-3 polyunsaturated fatty acids (n-3 PUFA) on
long-term outcome in renal transplant recipients (RTR) remains unclear. We investigated whether
marine-derived n-3 PUFA intake is associated with all-cause and cardiovascular (CV) mortality in
RTR. Intake of eicosapentaenoic acid plus docosahexaenoic acid (EPA-DHA) was assessed using
a validated Food Frequency Questionnaire. Cox regression analyses were performed to evaluate
the associations of EPA-DHA intake with all-cause and CV mortality. We included 627 RTR (age
53 ± 13 years). EPA-DHA intake was 102 (42–215) mg/day. During median follow-up of 5.4 years,
130 (21%) RTR died, with 52 (8.3%) due to CV causes. EPA-DHA intake was associated with lower
risk of all-cause mortality (Hazard Ratio (HR) 0.85; 95% confidence interval (95% CI) 0.75–0.97). Age
(p = 0.03) and smoking status (p = 0.01) significantly modified this association, with lower risk of
all-cause and CV mortality particularly in older (HR 0.75, 95% CI 0.61–0.92; HR 0.68, 95% CI 0.48–0.95)
and non-smoking RTR (HR 0.80, 95% CI 0.68–0.93; HR 0.74, 95% CI 0.56–0.98). In conclusion,
marine-derived n-3 PUFA intake is inversely associated with risk of all-cause and CV mortality in
RTR. The strongest associations were present in subgroups of patients, which adds further evidence
to the plea for EPA-DHA supplementation, particularly in elderly and non-smoking RTR.
Keywords: renal transplant recipients; omega-3 polyunsaturated fatty acids; cardiovascular mortality;
all-cause mortality
1. Introduction
Renal transplantation offers superior survival, quality of life, and cost-effectiveness in comparison
with chronic dialysis treatment [1–8]. Thus, it is considered the “gold standard” treatment for most
patients with end-stage renal disease. However, compared to age-matched controls in the general
population, the survival of renal transplant recipients (RTR) continues to be significantly lower [9], with
cardiovascular (CV) disease as the most important contributor to excess of mortality in RTR [10,11].
The consumption of polyunsaturated fatty acids may reduce the CV risk profile. Consequently,
several countries and organizations such as the World Health Organization have made
population-based diet recommendations for omega-3 polyunsaturated fatty acids (n-3 PUFA) intake.
Fish are the major food source of the n-3 PUFAs docosahexaenoic acid (DHA, C22:6 n-3) and
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eicosapentaenoic acid (EPA, C20:5 n-3). Thus, recommendations of EPA-DHA intake can easily
be met by following dietary guidelines such as those of the American Heart Association, which advises
consumption of at least two fish meals per week [11,12].
Evidence from both epidemiologic and interventional studies have shown that EPA and DHA
may exert beneficial effects on all-cause and CV mortality in both patients with pre-existing CV disease
as well as in healthy populations [13–19]. Prospective epidemiological studies have shown that weekly
fish intake is associated with lower rates of coronary heart disease (CHD) mortality in men [20–22].
It has also been shown in women that intake of fish and n-3 PUFA are inversely associated with risk of
CHD death [23]. Furthermore, in a study conducted across 36 countries, fish intake was associated
with a reduced risk from all-cause and ischemic heart disease mortality [24]. In addition, interventional
studies have reported a reduction in all-cause mortality in male survivors of a myocardial infarction
(MI), who were advised to increase their dietary intake of oily fish [25]. The largest randomized control
trial testing the efficacy of n-3 PUFA for secondary prevention of CHD so far included 11.324 patients.
It showed a 15% reduction in the primary end point of death, nonfatal MI, and nonfatal stroke, and a
20% reduction in all-cause mortality in patients receiving n-3 PUFA supplementation [26].
In RTR, a recent observational cohort study performed in a total of 1990 Norwegian patients
found that high levels of plasma phospholipid marine n-3 PUFA were independently associated with
better long-term survival late after renal transplantation [27]. However, this study was on plasma
biomarker status and not on intake per se. Hence, a recent systematic report from The Cochrane
Collaboration concluded that there is still insufficient evidence to recommend fish oil supplementation
to improve survival of RTR [28]. Nonetheless, in a recent study with relatively short follow-up, we
found a trend towards an inverse association of intake of marine-derived n-3 PUFA with all-cause
mortality in RTR [29].
We therefore set out to update data on intake of marine-derived n-3 PUFA and to extend follow-up
to increase power for prospective evaluation of the association of marine-derived n-3 PUFA intake with
all-cause and CV mortality in the cohort of stable outpatient RTR. For this purpose, we investigated the
intake of EPA and DHA, and evaluated its association with risk of all-cause and CV mortality in RTR.
2. Methods
2.1. Study Design
An observational prospective study was conducted in a large single center RTR cohort [30]. All
adult (≥18 years old) RTR with a functioning allograft for at least one year after transplantation and
without known or apparent systemic illnesses (i.e., malignancies, opportunistic infections) who visited
our outpatient clinic between November 2008 and March 2011 were invited to participate in this
prospective cohort study. From a total of 817 RTR invited to be enrolled, 707 (87%) patients signed
informed consent. We excluded all patients missing dietary or laboratory data, resulting in 627 RTR
eligible for the statistical analysis. The present study was conducted according to the guidelines
settled in the Declaration of Helsinki, and the Institutional Review Board approved the study protocol
(METc 2008/186).
The primary long-term endpoints of the current study were all-cause and CV mortality in RTR.
The continuous surveillance system of the outpatient program ensures up-to-date information on
patient status. We contacted general practitioners or referring nephrologists in cases the status of a
patient was unknown. The patients were followed until 30 September 2015, with no loss to follow-up.
2.2. Renal Transplant Characteristics
RTR were all transplanted in the University Medical Center Groningen and had no history of
drug or alcohol addiction according to their patient files. RTR were on standard antihypertensive
and immunosuppressive therapy. Except for discouraging excess sodium intake and encouraging
losing weight in overweight individuals, no specific dietary counseling was included as a routine
Nutrients 2017, 9, 363 3 of 12
regimen, nor was dietary recommendation regarding n-3 PUFA intake advised to participants.
Relevant characteristics including recipient age, gender, CV history, and transplant information were
extracted from patient records. Self-report questionnaires were used to obtain information on smoking
behavior and alcohol intake. Physical activity was assessed using the Short Questionnaire to Assess
Health-Enhancing Physical Activity (SQUASH) score in time multiplied by intensity [31].
2.3. Dietary Assessment
Dietary intake was assessed with a semi-quantitative validated food frequency questionnaire
(FFQ) that was developed at Wageningen University [32]. The questionnaire inquired about intake of
177 food items during the last month. For each item, the frequency was documented in times per day,
week, or month. The number of servings was recorded in natural units (for example, slice of bread or
apple) or household measures (for example, cup or spoon). The questionnaire was self-administered
and filled in at home. All FFQ were checked for completeness on the day of the visit to the outpatient
clinic by a trained researcher. The results of the FFQ were converted into total energy and nutrient
intake by using the Dutch Food Composition Table of 2006 [33].
2.4. Measurements
All measurements were performed once at baseline during a morning visit to the outpatient
clinic. Body weight and height were measured with patients wearing indoor clothing without shoes.
Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared
(kg/m2), and body surface area (BSA) was estimated in meters squared (m2) [34]. Blood pressure,
heart rate, and mean arterial pressure were measured according to a strict protocol and determined
with a semi-automatic device (Dinamap 1846, Critikon, Tampa, FL, USA). Blood pressure and heart
rate were measured every minute for 15 min, and the last three measurements were averaged [35].
Blood was drawn after a fasting period of 8–12 h, which included no medication intake. Diabetes
was defined as use of antidiabetic medication, fasting plasma glucose ≥7.0 mmol/L [36] or glycated
hemogloblin (HbA1C) higher than 6.5 as proposed by Shabir et al. [37]. Serum creatinine levels were
measured with a modified version of the Jaffé method (MEGA AU 510, Merck Diagnostica, Darmstadt,
Germany). Serum cystatin C concentrations were measured by Gentian Cystatin C Immunoassay
(Gentian AS, Moss, Norway) on a Modular analyzer (Roche Diagnostics, Mannheim, Germany). Renal
function was assessed by the estimated glomerular filtration rate (eGFR) based on the CKD-EPI
equation of creatinine/cystatine C developed as proposed by Terpos et al. [38].
Serum albumin, high-sensitivity C-reactive protein (hs-CRP), HbA1C, triglycerides, low-density
lipoprotein (LDL)-, high-density lipoprotein (HDL)-, and total cholesterol were measured according to
routine laboratory methods. According to a strict protocol, all RTR were asked to collect a 24-h urine
sample during the day before their visit to the outpatient clinic. Total urinary protein concentration
was determined using the Biuret reaction (MEGA AU 150, Merck Diagnostica, Darmstadt, Germany).
Proteinuria was defined as urinary protein excretion ≥0.5 g/24 h.
2.5. Statistical Analyses
Data analysis was performed using SPSS version 22.0 software (IBM Corp., Armonk, NY, USA),
STATA version 13 (StataCorp LP, College Station, TX, USA) and R version 3.2.3 (R Foundation for
Statistical Computing, Vienna, Austria). In all analyses, a two-sided p < 0.05 was considered significant.
Continuous variables were summarized using mean (standard deviation, SD) for normally distributed
data, whereas skewed distributed variables are given as median (interquartile range (IQR)); percentages
were used to summarize categorical variables. Marine-derived n-3 PUFA intake was accounted as the
sum of EPA and DHA intake (100 mg/day) adjusted for total energy intake (kJ/day) according to the
residual method [39].
Linear regression analyses were performed to evaluate the association of marine-derived n-3
PUFA intake with baseline characteristics. Natural log transformation was used for analyses of
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variables with a skewed distribution. Schoenfeld residuals of EPA-DHA intake (per 100 mg) were
checked: the assumption of proportional hazards was not violated (p = 0.65).
In prospective analyses, Cox-proportional hazard regression analyses were performed to
investigate the associations of marine-derived n-3 PUFA intake as continuous variable, with all-cause
and CV mortality in RTR. Analyses were performed with adjustment for age and sex (Model 1)
and additional adjustment for eGFR, proteinuria, and time between transplantation and baseline
measurement (Model 2). To avoid the inclusion of too many variables for the number of events, further
models were performed with additive adjustments to model 2. We performed additional adjustment
for smoking status, alcohol use, and physical activity (Model 3); for BMI, diabetes mellitus, and CV
history (Model 4); for LDL-, total cholesterol, triglycerides concentration, and systolic blood pressure
(Model 5); for hs-CRP and albumin concentration (Model 6). Hazard ratios (HR) of Cox-regression
models are reported with 95% confidence interval (CI).
In secondary analyses, we performed stratified analyses according to subgroups of age, sex, BMI,
diabetes, cardiovascular history, renal function, smoking status, alcohol use, and physical activity. We
also tested for interaction to identify potential effect modification.
3. Results
3.1. Baseline Characteristics
Baseline characteristics of RTR are shown in Table 1. A total of 627 patients were included. At a
median (IQR) of 5.7 (2.0–12.2) years after transplantation, participants were 53 ± 13 years old and
56.3% were male. The patients were slightly overweight (BMI 26.6 ± 4.7), and 152 (24.2%) had diabetes.
Mean blood pressure of RTR was within normal boundaries (136 ± 17/83 ± 11 mmHg). It should,
however, be noted that 552 (88%) of the 627 participants were using antihypertensive drugs. Mean
eGFR was 45 ± 19 mL/min/1.73 m2 and 139 (22.2%) patients had proteinuria. Mean serum total
cholesterol was 5.1 ± 1.1 mmol/L, while statins were taken by 333 (53.1%) of the RTR. Eighty-seven
percent of RTR reported the use of alcohol and 12.3% were current smokers. Smoking status was
unknown in 25 (4.0%) of RTR. Total energy intake was 8756 (7224–10,636) kJ/day. EPA, DHA, and
DHA-EPA intake were 39 (13–85), 60 (28–129), and 102 (42–215) mg/day, respectively.
Table 1. Baseline characteristics of RTR, and association of energy adjusted EPA-DHA intake across
clinical parameters.
Clinical Variables All Patients
EPA-DHA Intake (100 mg/Day)
Std.β p
No. of patients 627 - -
DHA, mg/day 60 (28–129) - -
EPA, mg/day 39 (13–85) - -
EPA-DHA, mg/day 102 (42–215) - -
Demographics
Age, years 53 ± 13 0.13 0.001
Ethnicity (caucasian), n (%) 625 (99.7) 0.03 0.46
Sex (male), n (%) 353 (56.3) 0.04 0.39
Body mass index, kg/m2 26.6 ± 4.7 0.08 0.04
Body surface area, m2 1.9 ± 0.2 0.01 0.78
Cardiovascular history, n (%) 251 (40.0) 0.04 0.28
Renal transplantation characteristics
Pre-emptive transplantation, n (%) 102 (16.3) 0.003 0.93
Time between transplantation and baseline, years 5.7 (2.0–12.2) −0.002 0.95
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Table 1. Cont.
Clinical Variables All Patients
EPA-DHA Intake (100 mg/Day)
Std.β p
Hemodynamic parameters
Systolic blood pressure, mmHg 136 ± 17 0.001 0.98
Diastolic blood pressure, mmHg 83 ± 11 0.03 0.41
Mean arterial pressure, mmHg 108 ± 15 0.02 0.71
Heart rate, beats per minute 69 ± 12 0.01 0.78
Antihypertensives, n (%) 552 (88.0) −0.04 0.34
Renal function parameters
Creatinine, umol/L 123 (99–159) 0.005 0.91
Cystatine-C, mg/L 1.7 (1.3–2.2) −0.06 0.13
eGFR, mL/min/1.73 m2 45 ± 19 −0.01 0.83
Proteinuria ≥0.5 g/day, n (%) 139 (22.2) −0.02 0.55
Glucose homeostasis
Glucose, mmol/L 5.3 (4.8–6.0) 0.06 0.14
HbA1C, % 5.8 (5.5–6.2) 0.05 0.27
Diabetes, n (%) 152 (24.2) 0.02 0.60
Antidiabetic medication, n (%) 98 (15.6) 0.02 0.67
Serum parameters
Albumin, g/L 43.0 ± 3.0 −0.02 0.67
hs-CRP, mg/L 1.6 (0.7–4.5) 0.06 0.13
Lipids
Total cholesterol, mmol/L 5.1 ± 1.1 0.08 0.06
LDL cholesterol, mmol/L 3.0 ± 0.9 0.06 0.13
HDL cholesterol, mmol/L 1.3 (1.1–1.7) 0.07 0.10
Triglycerides, mmol/L 1.7 (1.2–2.3) −0.01 0.75
Statin use, n (%) 333 (53.1) 0.02 0.57
Health lifestyle
Current smoker, n (%) 77 (12.3) −0.008 0.85
Alcohol consumers, n (%) 547 (87.2) −0.14 <0.001
Physical activity, intensity × hours 5250 (2400–8160) 0.03 0.41
Total energy intake, kJ/day 8756 (7224–10,636) - -
RTR, renal transplant recipients; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; eGFR, estimated
glomerular filtration rate; HbA1C, glycated hemoglobin; hs-CRP, high-sensitivity C-reactive protein; LDL,
low-density lipoprotein; HDL, high-density lipoprotein; kJ, kilojoule.
3.2. Association between Intake of Marine-Derived n-3 PUFA with Clinical Baseline Characteristics
The association between EPA-DHA intake with clinical baseline characteristics is shown in Table 1.
EPA-DHA intake was positively associated with age (std.β = 0.13, p = 0.001) and BMI (std.β = 0.08,
p = 0.04), and was negatively associated with alcohol use (std.β = −0.14, p < 0.001).
Results of multivariate Cox-proportional hazard regression analyses are shown in Table 2.
During follow-up of 5.4 (4.9–6.0) years, 130 (20.7%) RTR died. EPA-DHA intake was associated
with lower risk of all-cause mortality (Model 2: HR 0.85; 95% CI 0.75–0.97, p = 0.02) independent of
potential confounders including age, sex, eGFR, proteinuria, and time between transplantation and
baseline. This inverse association remained significant after additional adjustment for other potential
confounders. The association of EPA-DHA intake with CV mortality was of similar magnitude, but
did not reach statistical significance (Model 2: HR 0.83, 95% CI 0.68–1.02, p = 0.08).
In secondary analyses, we found effect modification of age (p = 0.03) and smoking status (p = 0.01)
on the association of EPA-DHA intake with all-cause mortality, independent of age and sex (Figure 1).
Consequently, we proceeded with further prospective stratified-analyses by subgroups of age (< or
≥63 years old) and smoking status (non-smokers or smokers), as depicted in Table S1 and Table
S2, respectively.
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EPA-DHA intake was associated with lower risk of all-cause mortality within the older subgroup
of patients (Model 2: HR 0.75; 95% CI 0.61–0.92, p = 0.01) but not within the younger subgroup of RTR
(Model 2: HR 0.98; 95% CI 0.85–1.18, p = 0.8). Likewise, EPA-DHA intake was associated with lower
risk of CV mortality within the older subgroup of RTR (Model 2: HR 0.68; 95% CI 0.48–0.95, p = 0.02),
but not in the younger subgroup of patients (Model 2: HR 1.02; 95% CI 0.80–1.29, p = 0.9).
Table 2. Prospective analysis of EPA-DHA intake (100 mg/day) on all-cause and CV mortality in RTR.
Model
EPA-DHA Intake, 100 mg/Day
HR (95% CI) p
All-cause mortality
Model 1 0.87 (0.77–0.99) 0.03
Model 2 0.85 (0.75–0.97) 0.02
Model 3 0.87 (0.77–1.00) 0.04
Model 4 0.87 (0.76–0.99) 0.03
Model 5 0.84 (0.73–0.96) 0.01
Model 6 0.85 (0.74–0.97) 0.02
CV mortality
Model 1 0.85 (0.69–1.05) 0.13
Model 2 0.83 (0.68–1.02) 0.08
Model 3 0.86 (0.70–1.07) 0.18
Model 4 0.84 (0.68–1.03) 0.10
Model 5 0.81 (0.64–1.01) 0.06
Model 6 0.82 (0.65–1.03) 0.08
RTR, renal transplant recipients; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; CV, cardiovascular.
Model 1: adjustment for age and sex. Model 2: model 1 + adjustment for estimated glomerular filtration Rate,
proteinuria, and time between transplantation and baseline measurement. Model 3: model 2 + adjustment
for smoking status, alcohol use, and physical activity. Model 4: model 2 + adjustment for body mass index,
diabetes mellitus and cardiovascular history. Model 5: model 2 + adjustment for total cholesterol, low-density
lipoprotein-cholesterol, triglycerides concentration, and systolic blood pressure. Model 6: model 2 + adjustment for
high-sensitivity C-reactive protein and albumin concentration.
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Figure 1. Stratified-analysis of the association of -DHA intake with all-cause mortality in RTR.
Hazard ratios adjusted for age and sex are shown. Subgroups with p-interaction < 0.05 were considered
effect modifiers on the association of EPA-DHA intake with all-cause mortality.
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4. Discussion
In this study, we show that marine-derived n-3 PUFA intake is inversely associated with risk
of all-cause mortality in a large cohort of stable outpatients RTR, and we show an association of
similar magnitude—though not statistically significant—of marine-derived n-3 PUFA intake on the
risk of CV mortality in RTR. We also show that age and smoking status are effect-modifiers of
the association of marine-derived n-3 PUFA intake with all-cause mortality. Accordingly, further
prospective age-stratified analysis shows that marine-derived n-3 PUFA intake is inversely associated
with risk of all-cause and CV mortality within the older (cut-off point 63 years old), but not the younger
subgroup of RTR. Likewise, prospective smoking status-stratified analysis shows that marine-derived
n-3 PUFA intake is inversely associated with risk of all-cause and CV mortality within the non-smoker
patient subgroup, but not within the subgroup of smoker RTR.
In the general population, it has been largely shown that marine-derived n-3 PUFA intake may
exert beneficial effects on both CV endpoints and all-cause mortality [13–19]. The mechanisms by which
increased ingestion of n-3 PUFAs exert favorable effects on CV health are not fully known; however, it
has been proposed that reducing susceptibility of the heart to ventricular arrhythmia, retarding growth
of atherosclerotic plaques, reducing adhesion molecule expression, reducing platelet-derived growth
factor, promoting nitric oxide-induced endothelial relaxation and anti-inflammatory effects may be
underlying mechanisms involved [13].
Up-to-date results regarding their potential beneficial effects on survival after renal transplantation
remain controversial thus far. Previously, Eide and colleagues reported that in a cohort of 1990
Norwegian RTR with 406 deaths events at a median follow-up of 6.8 years, higher plasma phospholipid
marine n-3 PUFA levels were independently associated with better patient survival in RTR [40].
Importantly, this study was not performed on intake per se, but on plasma biomarker status of
marine-derived n-3 PUFA, which is a resultant of intake and metabolism. However, a recent systematic
report from the Cochrane Collaboration concluded that there is still insufficient evidence to recommend
fish oil supplementation to improve survival of RTR [28]. On the basis of the latter statement, it seems
that the beneficial effect of marine-derived n-3 PUFA on survival of RTR remains under discussion.
Importantly, it is critical to consider that inconsistent results across the three randomized control
trials accounted in this systematic review (for the outcome of mortality in RTR) may arise from
methodological problems such as differing doses of fish oils, duration and timing of treatment, small
number of patients, and a number of events too low to establish definitive conclusions. Previously,
we reported a trend towards an inverse association of intake of marine-derived n-3 PUFA with
all-cause mortality in RTR, with relatively short follow-up of RTR [29]. The current study updated
data on n-3 PUFA intake and extended follow-up of our cohort. The findings of the current study
support the notion [17–19,27] that marine-derived n-3 PUFAs exert beneficial effects on long-term
survival after renal transplantation. Moreover, our findings support that favorable outcomes offered
by marine-derived n-3 PUFA intake may vary among different subgroups of RTR according to age and
smoking status.
It is not completely understood which are the underlying mechanisms that explain the effect
modification of age on the association of n-3 PUFA intake with mortality. Despite the fact that
chronic low-grade inflammation remains after renal transplantation and that many of the beneficial
effects of n-3 PUFA have been attributed to their anti-inflammatory properties [41], we did not find
an association of n-3 PUFA intake with inflammatory biomarkers. However, it has been shown
that independently of any influence on inflammation, n-3 PUFA may be an effective intervention
against anabolic resistance [42–45], which is known to be one of the main causes of age-related
sarcopenia. Animal studies have shown that n-3 PUFAs improve whole-body- as well as muscle
insulin-sensitivity [46]. Moreover, n-3 PUFA supplementation helps to maintain whole-body protein
metabolism via mTOR signaling pathways [47]. In healthy young adults, n-3 PUFA supplementation
has been shown to increase the anabolic response [43], and particularly in older adults, an increase of
muscle protein synthesis has been reported [42]. Thus, one might speculate that the effect modification
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of age on the association of n-3 PUFAs with mortality could be at least partly explained through the
beneficial effect of n-3 PUFAs on muscle protein synthesis.
Regarding smoking status as an effect modifier, it should be noted that it has previously been
suggested that oral supplementation of marine-derived n-3 PUFA may have effects that are distinct
between smokers and non-smokers [48]. Research regarding biomarkers of n-3 PUFA has already
shown that n-3 PUFA biomarkers are lower in smokers. It is noteworthy that this relationship was
independent of dietary intake of n-3 PUFAs [49]. Furthermore, it has been suggested that smoking
may affect fatty acid absorption and metabolism [50], including increased n-3 lipid peroxidation
in smokers [51,52]. Future studies are needed to better understand the effect of smoking on the
metabolism of n-3 PUFAs.
The strengths of our study include a median follow-up of 5.4 years with all-cause and CV
mortality as clinically relevant endpoints, without loss of participants due to follow-up. Furthermore,
our study included a large sample size of the specific setting of stable outpatient RTR. Moreover,
data was extensively collected, which allowed adjustment for many potential confounders of the
main results. On the other hand, we acknowledge that the current study has several limitations; for
example, marine-derived n-3 PUFA intake was measured using a self-reporting FFQ, which could lead
to possible over- or under-reporting of dietary intake. Moreover, dietary intake was only measured on
baseline and therefore changes in dietary intake during the follow-up period might not be accounted
for in our analysis. The higher the intra-individual variation of n-3 PUFA intake along the follow-up
period would be, the greater one would expect the benefit of repeated measurement for prediction
of outcomes [53,54]. Plasma biomarkers of n-3 PUFA were not available in this cohort study. Data
regarding plasma status of marine-derived n-3 PUFA could have provided better understanding of the
relation between dietary intake with plasma levels of marine-derived n-3 PUFA biomarkers. Further,
CV complications or interventions were not documented; therefore, we were unable to assess the effect
of dietary intake of n-3 PUFA on non-fatal CV-events. Additionally, our study population consisted
predominantly of Caucasian people, which calls for prudence to extrapolate our results to different
populations with regard to ethnicity. Finally, since the current study is observational by design, no
conclusions of causality can be drawn from our results.
5. Conclusions
In conclusion, marine-derived n-3 PUFA intake is inversely associated with a lower risk of
all-cause mortality in RTR. Furthermore, according to effect modifiers of this association, the beneficial
effects of marine-derived n-3 PUFA intake are different over subgroups of RTR. Thus, marine-derived
n-3 PUFA intake is inversely associated with all-cause and CV mortality in the older but not the
younger subgroup of patients. In turn, marine-derived n-3 PUFA intake is associated with lower
risk of all-cause and CV mortality in the non-smoker but not in the smoker subgroup of RTR. Our
findings support the protective effect of marine-derived n-3 PUFA intake on all-cause and CV mortality
that has been previously reported. We provide relevant data on intake complementary to existing
data on plasma biomarkers, further adding to the evidence that they are protective. However, due
to methodological heterogeneity across different studies, further design of multicenter, randomized,
double-blind, placebo-controlled trials aimed at testing the beneficial effects of marine-derived n-3
PUFA supplementation on mortality of RTR are still lacking.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/4/363/s1,
Table S1: Prospective age-stratified analysis of EPA-DHA intake (100 mg/day) on all-cause and CV mortality in
RTR, Table S2: Prospective smoking status-stratified analysis of EPA-DHA intake (100 mg/day) on all-cause and
CV mortality in RTR.
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